What research says about creatine and depression

The role creatine plays in supplying the brain with energy

Creatine is a naturally occurring compound that the liver, kidneys and pancreas make from three amino acids: glycine, arginine and methionine. We also get it from food, mainly meat and fish. Once absorbed, creatine enters cells and is phosphorylated into phosphocreatine, an energy-rich molecule that serves as a fast reserve for regenerating ATP.

ATP is the energy cells can use right away. Neurons spend ATP when they fire, pass on signals or maintain differences in ion concentration across their membranes. In hard-working tissues such as the brain, ATP stores can be used up quickly. Phosphocreatine acts as a buffer: it hands its phosphate group to ADP and regenerates ATP almost instantly. This system matters most in brain regions with high metabolic activity, such as the prefrontal cortex, which helps regulate mood, planning and self-control, among other things.

Magnetic resonance spectroscopy studies have shown that oral creatine supplements raise creatine and phosphocreatine levels in the brain. These increases suggest that creatine taken in from outside can cross the blood-brain barrier and may improve the brain’s ability to meet its energy needs.

The hypothesis: does an energy shortfall in the brain play a role in depression?

For a long time, explanations of depression focused mainly on messenger chemicals such as serotonin, norepinephrine and dopamine. These models shaped the development of many antidepressants, but they do not fully explain the illness or why people respond so differently to medication. Another hypothesis asks whether disturbances in cellular energy metabolism are also involved.

Imaging studies using phosphorus magnetic resonance spectroscopy have found lower phosphocreatine and ATP levels in the brains of people with major depression, particularly in the prefrontal cortex and the anterior cingulate cortex. These regions are central to emotional regulation, decision-making and cognitive control. According to this model, an inadequate energy supply could have several consequences:

Neurons work less efficiently.
Synaptic plasticity is impaired.
The brain becomes less able to adapt to stress.

Mitochondrial dysfunction has also been observed in depression. Mitochondria are the organelles that produce most of a cell’s ATP through oxidative phosphorylation. When mitochondria do not work properly, cells lean more heavily on less efficient anaerobic pathways, and the phosphocreatine system becomes even more important as a compensating energy buffer. By making more phosphocreatine available, creatine supplements may help keep the energy supply steady when nerve cells are under heavy demand.

Creatine also appears to influence several other pathways relevant to depression:

It modulates the growth factor BDNF, which supports the survival and adaptability of nerve cells.
It may affect neurotransmitter systems, including serotonin and dopamine signaling.
Some preclinical studies suggest that creatine protects nerve cells against oxidative stress and harmful overstimulation (excitotoxicity) (literature review 2016). Source

What observational data on creatine intake show

A large cross-sectional study using data from the National Health and Nutrition Examination Survey found an inverse association between dietary creatine intake and the prevalence of depression in US adults. People who got more creatine from their diet were less often found to have depression, even after accounting for confounders such as age, sex, physical activity and overall diet quality. A study of this kind cannot prove cause and effect, but it adds to the biological plausibility that creatine status may influence mood.

What clinical trials show about creatine in depression

A systematic review and meta-analysis published in the British Journal of Nutrition in 2025 pooled data from eleven randomized controlled trials with 1,093 participants. The combined analysis pointed to a small, possibly relevant reduction in depressive symptoms. As a benchmark, the source text cites a 3-point improvement as the smallest clinically meaningful difference, but it does not name the scale this refers to at that point. The confidence interval included zero, so the data are also compatible with a very small effect or none at all.

Heterogeneity between the studies was substantial, with an I² of 71.3%, meaning the results varied considerably from trial to trial. Some of this variation may be explained by differences in study populations. Trials in people with clinically diagnosed depression seemed to show larger effects than trials in people without depression, although subgroup analyses also showed signs of publication bias in favor of positive results.

One of the most frequently cited trials, published in the American Journal of Psychiatry in 2012, enrolled women with major depression who were already taking a selective serotonin reuptake inhibitor (SSRI) but had not reached full remission. Participants were randomly assigned to receive either 5 grams of creatine monohydrate a day or a placebo for eight weeks. Compared with the placebo group, the creatine group improved markedly more on depressive symptoms, and the effect showed up as early as two weeks in.

A dose-finding study in adolescent girls with SSRI-resistant depression used phosphorus magnetic resonance spectroscopy to measure brain phosphocreatine before and after supplementation. It found that higher creatine doses (10 grams a day) raised brain phosphocreatine more than lower doses (2 or 5 grams), and that these increases correlated with a reduction in depressive symptoms (literature review 2022). This points to a dose-response relationship and offers clues to a possible mechanism behind the clinical findings, although the sample was small. Source

Evidence on remission and response rates

The meta-analysis also looked at remission and treatment response. Remission, defined as a Hamilton Depression Rating Scale score below a set threshold, was clearly more likely in the creatine groups across three trials, with an odds ratio of 3.60. Treatment response, usually defined as a 50% reduction in symptom severity, did not differ significantly between creatine and placebo in the two trials that reported this outcome. So these differently defined endpoints give different results. They leave room for a possible benefit in some individuals, but they do not show a consistent improvement across all analyses.

Study limitations and possible bias

Under the GRADE criteria, the certainty of the evidence was rated very low, which means the true effect of creatine on depression remains highly uncertain (meta-analysis 2025). Several factors contribute to this rating: Source

Most trials were small, with 20 to 60 participants.
Many were run at a single center, which tends to produce larger treatment effects than multicenter trials.
Some trials did not adequately describe their randomization procedures or how group allocation was concealed.
Blinding was not always clearly maintained.
Selective outcome reporting was a problem, because not all trials registered their protocols in advance.
The source text also cites asymmetry in the funnel plot as a sign of publication bias, saying smaller trials showed larger effects. However, the evidence it links for this (meta-analysis 2023) concerns curcumin for heart damage in animal models. It cannot support this claim about creatine and depression; the correct reference remains unresolved. Source

Which doses and forms have been studied?

Doses studied

The dose studied most often in depression trials is 5 grams of creatine monohydrate a day, taken by mouth. Some trials used a loading phase (10 to 20 grams a day in the first week) followed by a maintenance dose, while others used the same daily dose throughout with no loading phase. The dose-finding study in adolescents suggested that 10 grams a day may raise brain phosphocreatine more than 5 grams. Whether this leads to better clinical outcomes has not yet been established. Creatine monohydrate is the form used in almost all clinical trials. It is inexpensive, well studied and highly bioavailable.

Timing and combining with other treatments

Creatine does not need to be taken at a particular time of day, because its effects depend on tissue saturation rather than on any single dose. Taking it consistently every day matters more than exact timing. Some evidence suggests that taking creatine with carbohydrates may improve uptake into muscle through insulin-mediated transport, but whether the same applies to uptake into the brain is unclear (literature review 2022). Creatine has been studied almost exclusively as an add-on to antidepressants rather than on its own. The reasoning is that creatine may act on energy metabolism as a complement, while SSRIs or SNRIs influence signaling through particular messenger chemicals. Source

How long to take it

Brain creatine levels rise gradually with supplementation and usually plateau after several weeks. Most trials ran for eight to twelve weeks, long enough to see changes in depressive symptoms if creatine works. Some reported early effects within two weeks, but lasting benefit over longer periods has not been studied adequately. It is not known whether creatine has to be taken indefinitely to keep any benefit, or whether the effect persists after stopping.

Who might benefit most, and who should be cautious?

So far, the clearest evidence for creatine in depression comes from trials in women with major depression who were already taking an SSRI but had not reached full remission. This suggests that creatine might be most useful as an add-on to existing treatment in people who have responded only partly, rather than as a first-line option. Whether men respond in a similar way is unclear, since most trials enrolled mainly or only female participants.

People with lower baseline brain creatine, as measured by magnetic resonance spectroscopy, may be more likely to benefit from supplementation. Outside research studies, however, brain creatine cannot be measured in routine care. Dietary creatine intake is another potential marker. People who eat little or no meat or fish (vegetarians and vegans, for example) have smaller natural creatine stores and may see a larger rise in brain creatine with supplementation. Adolescents and young adults with treatment-resistant depression have been studied in small trials, with some signs of benefit.

Creatine monohydrate is generally well tolerated at doses up to 10 grams a day. The side effects reported most often are mild digestive complaints and weight gain from water held in muscle tissue. The source text describes these side effects as mostly temporary; in the trials cited, they did not usually lead people to stop. There are concerns about kidney function, because creatine is broken down into creatinine, a waste product that the kidneys excrete. However, extensive research in healthy people and athletes has found no evidence that creatine supplements impair kidney function. People with existing kidney disease should consult a doctor before taking creatine.

The source text reports no apparent interactions with SSRIs, SNRIs or other common antidepressants. That does not mean every combination has been thoroughly tested and shown to be safe. In one small study, creatine was combined with 5-hydroxytryptophan, a serotonin precursor, without side effects, although this combination has not been studied in larger trials. The source text also claims there is no evidence that creatine worsens mania or raises suicide risk. This safety-relevant claim needs to be checked against the original studies. People with bipolar disorder should have close medical supervision when starting any new treatment.

How changes in the brain and in daily life can be measured

Unlike some supplements, where subjective symptom improvement is the only available endpoint, creatine’s effects on brain metabolism can be measured directly with phosphorus magnetic resonance spectroscopy. This technique quantifies phosphocreatine and ATP levels in specific brain regions, giving an objective measure of whether the presumed biological target is being affected. Studies using this approach found that rises in brain phosphocreatine correlate with reductions in depressive symptoms, which supports the hypothesis that energy metabolism is a relevant therapeutic target.

That said, magnetic resonance spectroscopy is not widely available and is not practical for routine clinical use. Without this direct measurement, clinicians and patients rely on symptom scales such as the Hamilton Depression Rating Scale or the Beck Depression Inventory to judge response. These scales capture changes in mood, sleep, appetite, energy and cognitive function, but they are subjective and can be swayed by placebo effects, expectations and reporting bias.

Changes in daily life, such as returning to work, social participation and quality of life, are arguably more meaningful than symptom scores, but few creatine trials have reported on these outcomes. Future studies should therefore do more to capture what changes in people’s lives. Metabolic measures taken before treatment could also matter. Fasting glucose, insulin and markers of mitochondrial function could in theory predict who is most likely to benefit from creatine, although this has not been tested. Inflammatory markers such as high-sensitivity C-reactive protein could be relevant too, since inflammation is increasingly being studied as a possible contributing factor in depression and may interact with energy metabolism.

Diet and metabolism as possible contributing factors

Depression usually has several contributing factors. The source text discusses energy metabolism, inflammation, nutrient deficiencies and hormonal changes as possible contributing causes or aggravating factors. Fasting glucose, hemoglobin A1c and insulin give information about sugar metabolism. Vitamin D, vitamin B12 and ferritin, along with inflammatory and thyroid markers, can answer further medical questions depending on symptoms. None of this adds up to a validated lab test that predicts whether creatine will help with depressive symptoms. Which tests make sense depends on an individual medical workup.

Frequently asked questions

Why might the brain have lower phosphocreatine levels in major depression?

Imaging studies with phosphorus magnetic resonance spectroscopy have found reduced phosphocreatine and ATP in the prefrontal cortex and anterior cingulate cortex of people with major depression. These regions govern emotional regulation and cognitive control. When mitochondrial function is impaired (a finding also observed in depression), cells depend more on the phosphocreatine buffer to regenerate ATP quickly. Less creatine in the brain means this buffer is smaller and neurons have less capacity to meet heavy signaling demands.

What did the 2025 meta-analysis find?

The 2025 British Journal of Nutrition meta-analysis pooled data from 11 RCTs with 1,093 participants. The pooled results showed a slight reduction in depressive symptom scores, and remission was clearly more likely in the creatine groups across three trials (odds ratio 3.60). However, heterogeneity was substantial, with an I² of 71.3%, the confidence interval for the primary effect included zero, and the certainty of the evidence was rated very low under the GRADE criteria. Funnel plot asymmetry also pointed to possible publication bias in favor of positive results.

Which groups of people have the clearest evidence?

The most consistent evidence comes from women with major depression who were already taking an SSRI but had not yet reached full remission. A 2012 American Journal of Psychiatry trial in this group found that 5 grams of creatine monohydrate a day for eight weeks led to markedly greater symptom improvement than placebo, with the effect appearing as early as two weeks in. Adolescent girls with SSRI-resistant depression also showed benefits in a dose-finding study, but the samples were small and the results need to be replicated in larger trials.

Which form and dose of creatine are used in depression trials?

Creatine monohydrate at 5 grams a day is the dose used most often in depression trials and the form studied in practically every published RCT. Some trials used loading phases of 10 to 20 grams a day in the first week before dropping to a maintenance dose. A dose-finding study in adolescents found that 10 grams a day raised brain phosphocreatine more than 5 grams, and higher brain levels went along with greater symptom reduction. Whether this translates into clinically meaningful better outcomes has not yet been confirmed in larger trials.

Does creatine need to be taken at a specific time of day to support its effect on mood?

Creatine does not need to be taken at any particular time of day, because its mood-related effects depend on gradual tissue saturation rather than on short-term peaks in blood levels. Taking it consistently every day matters more than exact timing. Brain creatine levels usually plateau after several weeks of supplementation, whatever time of day the dose is taken. Some evidence suggests that taking creatine with carbohydrates may increase uptake into muscle via insulin signaling, but whether this also applies to uptake into the brain has not been established.

Why might vegetarians and vegans benefit more from creatine supplements for depression?

Creatine comes mainly from meat and fish. Vegetarians and vegans get practically no creatine from their diet, so their starting creatine stores in muscle and brain are lower than those of people who also eat meat and fish. Lower starting stores leave more room for supplements to raise tissue creatine levels, and studies with phosphorus magnetic resonance spectroscopy have confirmed that this group shows a larger absolute rise in brain creatine after supplementation. If an energy shortfall in the brain contributes to depressive symptoms, people who start with lower creatine levels might benefit more.

What are the biggest methodological weaknesses of existing studies on creatine and depression?

The certainty of the evidence was rated very low under the GRADE criteria. Most trials had only 20 to 60 participants, so they could not reliably detect small effects or differences between subgroups. Single-center trials often report larger effects than multicenter trials. Some trials described their randomization procedures and allocation concealment inadequately. Blinding could not always be verified. Selective outcome reporting and asymmetric funnel plots also raise the question of whether small positive trials were more likely to be published than trials that found no detectable effect. The source text cites two meta-analyses for this, but one of them is attributed to the wrong topic; this reference needs to be corrected.

Can lab values predict who will respond to creatine?

Research has not yet tested this directly, but several metabolic biomarkers are conceivable candidates. Fasting glucose, insulin and hemoglobin A1c reflect cellular energy metabolism: impaired glucose regulation could point to an energy shortfall in the brain that might respond better to creatine. A deficiency in vitamin D, vitamin B12 or iron (shown, among other things, by low ferritin) can mimic or worsen depressive symptoms through various pathways, and correcting these deficiencies may do more for these people than creatine. Raised hs-CRP could also be relevant, since inflammation interacts with energy metabolism and could influence who responds to treatments that target it.

Sources and references

Bender A, Klopstock T (2016). Creatine for neuroprotection in neurodegenerative disease: end of story?. Amino acids, 48(8), 1929-40. https://doi.org/10.1007/s00726-015-2165-0 Publication

Forbes SC, Cordingley DM, Cornish SM, Gualano B, Roschel H, Ostojic SM, Rawson ES, Roy BD, Prokopidis K, Giannos P, Candow DG (2022). Effects of Creatine Supplementation on Brain Function and Health. Nutrients, 14(5). https://doi.org/10.3390/nu14050921 Publication

Eckert I, Lima J, Dariva AA (2025). Creatine supplementation for treating symptoms of depression: a systematic review and meta-analysis. The British journal of nutrition, 134(11), 947-959. https://doi.org/10.1017/S0007114525105588 Publication

Zeng YF, Guo QH, Wei XY, Chen SY, Deng S, Liu JJ, Yin N, Liu Y, Zeng WJ (2023). Cardioprotective effect of curcumin on myocardial ischemia/reperfusion injury: a meta-analysis of preclinical animal studies. Frontiers in pharmacology, 14, 1184292. https://doi.org/10.3389/fphar.2023.1184292 Publication

Candow DG, Forbes SC, Roberts MD, Roy BD, Antonio J, Smith-Ryan AE, Rawson ES, Gualano B, Roschel H (2022). Creatine O’Clock: Does Timing of Ingestion Really Influence Muscle Mass and Performance?. Frontiers in sports and active living, 4, 893714. https://doi.org/10.3389/fspor.2022.893714 Publication